Huma Therapeutics has been granted Class II clearance from the FDA for its Software-as-a-Medical-Device (SaMD) disease management platform, dramatically expanding the range of services it can deliver.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has said it will launch a pilot programme in the coming weeks to see how it can evolve the regulation of artificial intelligence as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback